News

NEJM corrects its study on rofecoxib

BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7557.12-b (Published 29 June 2006) Cite this as: BMJ 2006;333:12
  1. Susan Mayor
  1. London

    An increase in cardiovascular events associated with the cyclooxygenase-2 inhibitor rofecoxib (Vioxx) occurred much earlier in the course of treatment than the original study reporting the problem had indicated, says a correction published online in the New England Journal of Medicine on 26 June (http://content.nejm.org/, doi: 10.1056/NEJMx06).

    The correction to the study of …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe